文章：

单克隆抗体免疫疗法治疗急性髓系白血病：进展中的研究

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

原文发布日期：19 October 2023

DOI: 10.3390/cancers15205060

类型: Article

开放获取: 是

英文摘要：

In the last few years, molecularly targeted agents and immune-based treatments (ITs) have significantly changed the landscape of anti-cancer therapy. Indeed, ITs have been proven to be very effective when used against metastatic solid tumors, for which outcomes are extremely poor when using standard approaches. Such a scenario has only been partially reproduced in hematologic malignancies. In the context of acute myeloid leukemia (AML), as innovative drugs are eagerly awaited in the relapsed/refractory setting, different ITs have been explored, but the results are still unsatisfactory. In this work, we will discuss the most important clinical studies to date that adopt ITs in AML, providing the basis to understand how this approach, although still in its infancy, may represent a promising therapeutic tool for the future treatment of AML patients.

摘要翻译： 

近年来，分子靶向药物与免疫疗法已显著改变抗癌治疗的格局。事实上，免疫疗法在治疗转移性实体瘤方面已被证实具有显著疗效，而传统治疗方案对该类肿瘤的疗效极为有限。然而，这一成功模式在血液系统恶性肿瘤中仅得到部分复现。在急性髓系白血病领域，尽管临床迫切期待针对复发/难治性病例的创新药物，但多种免疫疗法的探索结果仍不尽如人意。本文系统梳理了迄今为止急性髓系白血病免疫治疗领域的重要临床研究，为理解该疗法虽处于发展初期、却可能成为未来急性髓系白血病患者重要治疗选择的理论基础提供依据。

原文链接：

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress